Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
"Best Ask" is the lowest price currently being asked for a block of stock.
"Today's Low" The lowest sales price the stock has fallen to during the regular trading hours, the intra-day low.
"52 Week Low" is the lowest sales price the stock has fallen to during the regular trading hours during the most recent 52 week period.
The current last sale of $16.25 is 11.61% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 16.604||$ 24.935|
|Low:||$ 15.83||$ 14.56|
Company Description (as filed with the SEC)
We are a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Leveraging our expertise in ophthalmology, gene therapy and drug development, we are developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases for which there are no currently approved treatments. Our lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase 3 clinical development in the first half of 2018 and represents the most clinically advanced product candidate for this indication worldwide. In data from 32 patients treated with NSR-REP1 across four open-label clinical trials, over 90% of treated patients maintained their visual acuity over a one-year follow-up period. ... More ...